Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy.
Margaret R Smith et al. NPJ precision oncology 2023 3 (1) 34
Evaluating Colonoscopy Screening Intervals in Patients with Lynch Syndrome from a Large Canadian Registry
M Aronson et al, JNCI, March 25, 2023
Top advances of the year: Precision oncology.
Aakash Desai et al. Cancer 2023 3
Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database
MD Valentin et al, EClinicalMedicine, March 2023
Fionnuala Crowley et al. The oncologist 2023
Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Francesco Cortiula et al. European journal of cancer (Oxford, England : 1990) 2023 184172-178
Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer.
Yongcheng Chen et al. Gland surgery 2023 12(2) 197-207
CACSV: a computational web-sever that provides classification for cancer somatic genetic variants from different tissues.
Nahla AlKurabi et al. BMC bioinformatics 2023 24(1) 95
Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study.
Steven J Katz et al. JCO oncology practice 2023 OP2200677
Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.
Zihui Yang et al. BMC cancer 2023 23(1) 243
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Katherine I Foster et al. Cancer 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Sandra Pinet et al. Frontiers in oncology 2023 131104659
Concordance between 21-gene recurrence score assay and clinicopathological predictive models in early-breast cancer patients cared for at a cancer center in Colombia.
Mauricio Luján et al. Gaceta medica de Mexico 2023 159(1) 3-9
Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
Xin Wang et al. The oncologist 2023
About Cancer PHGKB
Cancer PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to cancer...more
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: